Petros Pharmaceuticals Inc (PTPI)
0.58
+0.03
(+5.82%)
USD |
NASDAQ |
May 17, 16:00
0.58
0.00 (0.00%)
After-Hours: 20:00
Petros Pharmaceuticals SG&A Expense (Quarterly): 2.879M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.879M |
| September 30, 2023 | 2.002M |
| June 30, 2023 | 2.250M |
| March 31, 2023 | 2.131M |
| December 31, 2022 | 2.924M |
| September 30, 2022 | 2.171M |
| June 30, 2022 | 3.217M |
| March 31, 2022 | 3.898M |
| Date | Value |
|---|---|
| December 31, 2021 | 4.182M |
| September 30, 2021 | 3.413M |
| June 30, 2021 | 4.116M |
| March 31, 2021 | 3.882M |
| December 31, 2020 | 3.678M |
| September 30, 2020 | 3.121M |
| June 30, 2020 | 4.060M |
| March 31, 2020 | 4.816M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.002M
Minimum
Sep 2023
4.816M
Maximum
Mar 2020
3.296M
Average
3.315M
Median
SG&A Expense (Quarterly) Benchmarks
| Avalo Therapeutics Inc | 3.193M |
| Imunon Inc | 1.718M |
| iBio Inc | 2.961M |
| Ocugen Inc | 6.404M |
| Gritstone Bio Inc | 8.502M |